|
Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
| ||
NOT A SUBSCRIBER?Glaxo snares Stiefel LabsPosted on April 20, 2009 6:30 PM
The U.K.'s GlaxoSmithKline plc announced plans Monday to buy Stiefel Laboratories Inc. for up to $3.6 billion in a deal that will almost triple the size of its dermatology unit.
GlaxoSmithKline, of London, agreed to pay $2.9 billion in cash for Stiefel and to assume $400 million of net debt. The company may pay an additional $300 million if certain performance targets are met. This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools. To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button. Dig deeper, with Pipeline.
Most searched keywords
|
|
EXISTING USERS Missing a product? |
Michael Crosby mcrosby@thedeal.com 212.313.9325 |
Martha Brown mbrown@thedeal.com 212.313.9218 |